Kolkhof, Peter

Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes

Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine

Chronic Kidney Disease and DiabetesHormonal Regulation and Hypertension

Cited by 2,935

Cardiovascular events with finerenone in kidney disease and type 2 diabetes

Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine

Chronic Kidney Disease and DiabetesHormonal Regulation and Hypertension

Cited by 1,814

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis

Agarwal, R., Filippatos, G., Pitt, B., Anker, S. D., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Gebel, M., Ruilope, L. M., et al. (2022) · European Heart Journal

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 1,317

Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Solomon, S. D., McMurray, J. J. V., Vaduganathan, M., Claggett, B., Jhund, P. S., Desai, A. S., Henderson, A. D., Lam, C. S. P., Pitt, B., Senni, M., et al. (2024) · New England Journal of Medicine

Heart Failure Treatment and ManagementHormonal Regulation and Hypertension

Cited by 893

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial

Bakris, G. L., Agarwal, R., Chan, J. C., Cooper, M. E., Gansevoort, R. T., Haller, H., Remuzzi, G., Rossing, P., Schmieder, R. E., Nowack, C., et al. (2015) · JAMA

Chronic Kidney Disease and DiabetesHormonal Regulation and Hypertension

Cited by 708

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine

Agarwal, R., Kolkhof, P., Bakris, G., Bauersachs, J., Haller, H., Wada, T., & Zannad, F. (2021) · European Heart Journal

Hormonal Regulation and HypertensionRenin-Angiotensin System Studies

Cited by 638

Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury

Kolkhof, P., Delbeck, M., Kretschmer, A., Steinke, W., Hartmann, E., Bärfacker, L., Eitner, F., Albrecht-Küpper, B., & Schäfer, S. (2014) · Journal of Cardiovascular Pharmacology

Hormonal Regulation and HypertensionRenin-Angiotensin System Studies

Cited by 430

Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial

Filippatos, G., Anker, S. D., Agarwal, R., Ruilope, L. M., Rossing, P., Bakris, G. L., Tasto, C., Joseph, A., Kolkhof, P., Lage, A., et al. (2022) · Circulation

Chronic Kidney Disease and DiabetesHeart Failure Treatment and Management

Cited by 299

Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes

Filippatos, G., Anker, S. D., Agarwal, R., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Schloemer, P., Tornus, I., Joseph, A., et al. (2021) · Circulation

Chronic Kidney Disease and DiabetesHormonal Regulation and Hypertension

Cited by 294

Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic Activity

Grune, J., Beyhoff, N., Smeir, E., Chudek, R., Blumrich, A., Ban, Z., Brix, S., Betz, I. R., Schupp, M., Foryst-Ludwig, A., et al. (2018) · Hypertension

Cardiac Fibrosis and RemodelingHormonal Regulation and Hypertension

Cited by 292

Hyperkalemia risk with finerenone: results from the FIDELIO-DKD Trial

Agarwal, R., Joseph, A., Anker, S. D., Filippatos, G., Rossing, P., Ruilope, L. M., Pitt, B., Kolkhof, P., Scott, C., Lawatscheck, R., et al. (2022) · Journal of the American Society of Nephrology

Potassium and Related DisordersChronic Kidney Disease and Diabetes

Cited by 262

Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial

Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Nowack, C., Kolkhof, P., Ferreira, A. C., Schloemer, P., Filippatos, G., et al. (2019) · American Journal of Nephrology

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 184

The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling

Barrera-Chimal, J., Estrela, G. R., Lechner, S. M., Giraud, S., El Moghrabi, S., Kaaki, S., Kolkhof, P., Hauet, T., & Jaisser, F. (2018) · Kidney International

Acute Kidney Injury ResearchChronic Kidney Disease and Diabetes

Cited by 183

Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside

Kolkhof, P., Jaisser, F., Kim, S.-Y., Filippatos, G., Nowack, C., & Pitt, B. (2016) · Handbook of Experimental Pharmacology

Hormonal Regulation and HypertensionHeart Failure Treatment and Management

Cited by 180

Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes

Filippatos, G., Bakris, G. L., Pitt, B., Agarwal, R., Rossing, P., Ruilope, L. M., Butler, J., Lam, C. S. P., Kolkhof, P., Roberts, L., et al. (2021) · Journal of the American College of Cardiology

Atrial Fibrillation Management and OutcomesChronic Kidney Disease and Diabetes

Cited by 153

Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage

Kolkhof, P., Hartmann, E., Freyberger, A., Pavkovic, M., Mathar, I., Sandner, P., Droebner, K., Joseph, A., Hüser, J., & Eitner, F. (2021) · American Journal of Nephrology

Chronic Kidney Disease and DiabetesHormonal Regulation and Hypertension

Cited by 143

Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone

Agarwal, R., Anker, S. D., Bakris, G., Filippatos, G., Pitt, B., Rossing, P., Ruilope, L., Gebel, M., Kolkhof, P., Nowack, C., et al. (2022) · Nephrology Dialysis Transplantation

Chronic Kidney Disease and DiabetesHormonal Regulation and Hypertension

Cited by 103

Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial

Heerspink, H. J. L., Birkenfeld, A. L., Cherney, D. Z. I., Colhoun, H. M., Ji, L., Mathieu, C., Groop, P.-H., Pratley, R. E., Rosas, S. E., Rossing, P., et al. (2023) · Diabetes Research and Clinical Practice

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 63

Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF

Yang, M., Henderson, A. D., Talebi, A., Atherton, J. J., Chiang, C.-E., Chopra, V., Comin-Colet, J., Kosiborod, M. N., Kerr Saraiva, J. F., Claggett, B. L., et al. (2025) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementHormonal Regulation and Hypertension

Cited by 41